Finally, we selected TUBB2A with the most significant difference for IP validation, and WB results showed that TUBB2A was involved in the lactylation modification process in GBM and was significantly stronger than the control group (Figure 10I). The gene discussed is TUBB2A; the disease is glioblastoma.